Red Flags Detected

  • Material Weakness (new) — Insufficient accounting staff for risk assessment and segregation of duties, plus lack of GAAP expertise for complex transactions and specialist valuations.
NASDAQ: AIDX 20/20 Biolabs, Inc. 10-K

AIDX debuts on Nasdaq with $40M equity line, material control weaknesses, and $3.7M loss

Filed March 31, 2026 · Period ending December 31, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade AIDX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.